Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Dutasteride effectively treats enlarged prostate with manageable side effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

These new skin treatments are safer and more effective with minimal side effects.

Baicalin may help treat severe drug-induced skin reactions.

Deleting Smad4 and PTEN genes in mice causes rapid, invasive forestomach cancer.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Upadacitinib effectively treats severe alopecia areata and is safe.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.